WT1 HLA class II-binding peptides and compositions and methods comprising same

Patent metadata

Field	Value
Publication number	US-12528849-B2
Application number	US-202217744465-A
Country	US
Kind code	B2
Filing date	May 13, 2022
Priority date	Oct 17, 2005
Publication date	Jan 20, 2026
Grant date	Jan 20, 2026

Abstract

This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.

First claim

What is claimed is:

1 . A nucleic acid comprising a nucleic acid sequence encoding a peptide consisting of the amino acid sequence RSDELVRHHNMHQRNMTKL (SEQ ID No: 2), a nucleic acid sequence encoding a peptide consisting of the amino acid sequence PGCNKRYFKLSHLQMHSRKHTG (SEQ ID No: 4), and one or more additional nucleic acid sequences encoding one or more peptides, respectively, wherein each of said one or more peptides independently consists of the amino acid sequence selected from the group consisting of SEQ ID NO: 5-38.

2 . The nucleic acid of claim 1 , wherein the additional nucleic acid sequence encodes a peptide consisting of the amino acid sequence YMFPNAPYL (SEQ ID NO: 6).

3 . A composition comprising the nucleic acid of claim 1 .

4 . An expression vector comprising the nucleic acid of claim 1 .

5 . The expression vector of claim 4 , wherein the additional nucleic acid encodes a peptide consisting of the amino sequence YMFPNAPYL (SEQ ID NO:6).

6 . The expression vector of claim 4 , further encoding an immunomodulatory compound.

7 . The expression vector of claim 6 , wherein the immunomodulatory compound is a cytokine, chemokine, or complement component that enhances expression of immune system accessory or adhesion molecules, their receptors, or a combination thereof.

8 . The expression vector of claim 6 , wherein the immunomodulatory compound is any of interleukins 1 to 15 interferons alpha, beta or gamma, tumour necrosis factor, granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), granulocyte colony stimulating factor (G-CSF), neutrophil activating protein (NAP), macrophage chemoattractant and activating factor (MCAF), RANTES, or macrophage inflammatory peptides MIP-1a or MIP-1b.

9 . A vaccine comprising the expression vector of claim 4 .

10 . The vaccine of claim 9 , further comprising an adjuvant, carrier or antigen presenting cell.

11 . The vaccine of claim 10 , wherein the adjuvant is QS21, Freund's incomplete adjuvant, aluminum phosphate, aluminum hydroxide, Bacille Calmette Guerin (BCG), alum, a growth factor, a cytokine, a chemokine, an interleukin, a composition comprising a natural metabolizable oil and a refined emulsifier, or GM-CSF.

12 . A method of treating a subject with a WT1-expressing cancer, the method comprising administering to said subject the nucleic acid of claim 1 , or composition or expression vector thereof, thereby treating a subject with a WT1-expressing cancer.

13 . The method of claim 12 , wherein said WT1-expressing cancer is a leukemia, a desmoplastic small round cell tumor, a gastric cancer, a colon cancer, a lung cancer, a breast cancer, a germ cell tumor, an ovarian cancer, a uterine cancer, a thyroid cancer, a liver cancer, a renal cancer, a Kaposi's sarcoma, a sarcoma, or a hepatocellular carcinoma.

14 . The method of claim 12 , wherein said WT1-expressing cancer is a Wilms' tumor, an acute myelogenous leukemia (AML), a myelodysplastic syndrome (MDS), or a non-small cell lung cancer (NSCLC).

15 . A method of reducing an incidence of a WT1-expressing cancer, or its relapse, in a subject, the method comprising administering to said subject the nucleic acid of claim 1 , or composition or expression vector thereof, thereby reducing an incidence of a WT1-expressing cancer, or its relapse, in a subject.

16 . The method of claim 15 , wherein said WT1-expressing cancer is a leukemia, a desmoplastic small round cell tumor, a gastric cancer, a colon cancer, a lung cancer, a breast cancer, a germ cell tumor, an ovarian cancer, a uterine cancer, a thyroid cancer, a liver cancer, a renal cancer, a Kaposi's sarcoma, a sarcoma, or a hepatocellular carcinoma.

17 . The method of claim 15 , wherein said WT1-expressing cancer is a Wilms' tumor, an acute myelogenous leukemia (AML), a myelodysplastic syndrome (MDS), or a non-small cell lung cancer (NSCLC).

18 . A method of inducing the formation and proliferation of cytotoxic T lymphocytes (CTL) specific for cells of a WT1-expressing cancer, the method comprising administering to said subject the nucleic of claim 1 , or a composition or expression vector thereof, thereby inducing the formation and proliferation of CTL specific for cells of a WT1-expressing cancer.

19 . The method of claim 18 , wherein said WT1-expressing cancer is a leukemia, a desmoplastic small round cell tumor, a gastric cancer, a colon cancer, a lung cancer, a breast cancer, a germ cell tumor, an ovarian cancer, a uterine cancer, a thyroid cancer, a liver cancer, a renal cancer, a Kaposi's sarcoma, a sarcoma, or a hepatocellular carcinoma.

20 . The method of claim 18 , wherein said WT1-expressing cancer is a Wilms' tumor, an acute myelogenous leukemia (AML), a myelodysplastic syndrome (MDS), or a non-small cell lung cancer (NSCLC).

21 . A method of inducing an anti-mesothelioma immune response in a subject, the method comprising the step of administering to said subject the nucleic acid of claim 1 , or composition or expression vector thereof, thereby inducing an anti-mesothelioma immune response in a subject.

22 . A method of treating a subject with a mesothelioma, the method comprising the step of administering to said subject the nucleic acid of claim 1 , or a composition or expression vector thereof, thereby treating a subject with a mesothelioma.

23 . A method of reducing an incidence of a mesothelioma, or its relapse, in a subject, the method comprising the step of administering to said subject the nucleic acid of claim 1 , or composition or expression vector thereof, thereby reducing an incidence of a mesothelioma, or its relapse, in a subject.

Assignees

• Memorial Sloan Kettering Cancer Center

Inventors

• Scheinberg David
• Pinilla-Ibarz Javier
• May Rena

Classifications

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• A61K40/4243

  Wilms tumor 1 [WT1] · CPC title

• A61K40/428

  Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K39/001153

  Wilms tumor 1 [WT1] · CPC title